title: Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients--long-term follow-up and continuing experience.
authors.forename: G
authors.initials: G
authors.lastname: Auerswald
authors.forename: C
authors.initials: C
authors.lastname: Bidlingmaier
authors.forename: K
authors.initials: K
authors.lastname: Kurnik
mesh_terms: D019774:Blood Coagulation Factor Inhibitors / Q000097:blood*; D003029:Coagulants / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005169:Factor VIII / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance; D007223:Infant; D013997:Time Factors
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D003029:Coagulants; D005169:Factor VIII